|
Originally published In Press as doi:10.1074/jbc.M209075200 on October 16, 2002
J. Biol. Chem., Vol. 277, Issue 52, 50333-50340, December 27, 2002
The Protein-tyrosine Phosphatase CD45 Reaches the Cell Surface
via Golgi-dependent and -independent Pathways*
Troy A.
Baldwin and
Hanne L.
Ostergaard§
From the Department of Medical Microbiology and Immunology,
University of Alberta, Edmonton, Alberta T6G 2S2, Canada
Received for publication, September 5, 2002, and in revised form, October 15, 2002
 |
ABSTRACT |
CD45 is a receptor protein-tyrosine phosphatase
essential for T cell development and lymphocyte activation. It is
highly glycosylated, with multiple isoforms and glycoforms expressed on
the cell surface depending on the cell type and stage of
differentiation. Interestingly, we found two pools of newly synthesized
CD45 expressed on plasma membrane, one of which arrived by 5 min
after synthesis. The remaining pool of CD45 was fully glycosylated and
began to arrive at the cell surface at ~15 min. The rapidly expressed
population of CD45 possessed exclusively endoglycosidase H-sensitive
N-linked carbohydrate. Additionally, this rapidly expressed
pool of CD45 appeared on the cell surface in a brefeldin A
(BFA)-insensitive manner, suggesting that it reached the cell surface
independent of the Golgi complex. The remaining CD45 trafficked through
the Golgi complex, and transport proceeded via a BFA-sensitive
mechanism. These data suggest that CD45 is able to reach the cell
surface via two distinct routes. The first is a conventional
Golgi-dependent pathway that allows fully processed CD45 to
be expressed. The second utilizes an ill defined mechanism that is
independent of the Golgi, is BFA-resistant, and allows for the
expression of CD45 with immature carbohydrate on the cell surface.
 |
INTRODUCTION |
The transmembrane protein-tyrosine phosphatase CD45 is required
for both thymocyte development and T cell activation (1, 2). CD45
exerts its effects, at least in part, by regulating the phosphorylation
state of Src family kinases through the dephosphorylation of a negative
regulatory carboxyl-terminal tyrosine residue (3, 4). In addition to
the cytoplasmic phosphatase domains, CD45 contains a large
extracellular region. Three alternatively spliced exons reside within
the external domain of CD45 and contain numerous sites for potential
O-linked carbohydrate additions. These exons are
developmentally regulated with respect to usage in T cells; and
therefore, cells at different developmental stages have the potential
to express vastly different forms of CD45. In addition to the
O-linked carbohydrate found in the alternatively spliced sequences, there are numerous potential N-linked
carbohydrate attachment sites (5). These N-linked
carbohydrate additions have been demonstrated to be important for both
cell-surface expression and stability of CD45 (6). In addition, we have
recently shown that the composition of the CD45 N-linked
carbohydrate is developmentally regulated, possibly through the action
of the endoplasmic reticulum (ER)1 enzyme glucosidase II
(GII) (7). Intriguingly, no typical cell-surface ligand for the
extracellular domain of CD45 has been identified; however, several
lectins have been demonstrated to bind CD45 carbohydrate (7-12).
The intracellular transport of proteins from the ER to the cell surface
is a tightly controlled process involving the coordinated action of
many enzymes and proteins (13). For the most part, as a protein moves
through the secretory pathway, a level of control is exerted at each
stage of the transport process, from protein folding and vesicle
budding at the ER to movement through the Golgi stacks and finally
sorting at the trans-Golgi network (TGN) en route to its
final destination (14). In many cases, this regulation is necessary for
proper function of the protein. For example, transport of Class I and
II major histocompatibility complex (MHC) antigen-presenting proteins
as well as CD1 follows different routes to the cell surface, and those
specific routes are necessary to ensure that the appropriate antigens
are loaded into their peptide- or glycolipid-binding grooves (15-17).
For CD45, it is clear that cell-surface expression is required for proper function and that the N-linked carbohydrate on CD45
plays a role in this process (6). Recently, mannose-binding lectin has
been shown to bind cell-surface CD45, which indicates that CD45 is able
to escape complete carbohydrate processing, leaving immature, high
mannose carbohydrate (7, 12). Alternative trafficking routes are one
possible mechanism CD45 could employ to reach the plasma membrane
without complete carbohydrate processing. With the recent examples of
carbohydrate influencing biological function such as dendritic
cell-specific ICAM-grabbing non-integrin interactions (18, 19), CD8-MHC
interactions (20, 21), and T cell receptor clustering (22), as
well as the limited information on CD45 trafficking in general, we set
out to determine the overall trafficking patterns of CD45. By examining
the transport of CD45 to the plasma membrane, we hoped to gain insight
into the mechanism of expression of CD45 bearing mannose-binding lectin ligands.
Our results indicate that there is a pool of CD45 that is very rapidly
expressed on the cell surface after synthesis. It appears that two
different mechanisms exist that allow CD45 to reach the cell surface:
one involving the Golgi complex, resulting in endoglycosidase H (Endo
H)-resistant carbohydrate modification; and the other independent of
the Golgi, resulting in the maintenance of exclusively Endo H-sensitive
carbohydrate on the cell surface. These data support the existence of a
transport pathway where cargo can reach the cell surface extremely
rapidly, without the requirement of the Golgi complex.
 |
MATERIALS AND METHODS |
Cell Lines and Antibody Reagents--
The T lymphoma cell line
BW5147 (referred to below as BW) was maintained as previously
described (23). The CD45RO-expressing fibroblast cell line 2 50.5 was provided by Dr. Pauline Johnson (University of British Columbia,
Vancouver, British Columbia, Canada) (24). The anti-pan CD45
extracellular domain monoclonal antibody I3/2 was described previously
(23). The anti-Class I MHC Db antiserum H137 (25) was
kindly provided by Dr. Kevin Kane (University of Alberta). Rabbit
antisera H2 and J37, specific for GII and the intracellular region
of CD45, respectively, were previously described (26). Rabbit
anti-Pyk-2 antiserum was previously described (27). Anti-GII
antiserum was purchased from Stressgen Biotechnologies Corp. (Vancouver).
Cell-surface Biotinylation, Cell Lysis, Immunoprecipitation,
Streptavidin Pull-down Assay, and Endoglycosidase
Treatment--
Cell-surface biotinylation was performed as previously
described (7). Briefly, cells were biotinylated with 50 µl of 10 mM sulfosuccinimidobiotin (Pierce)/5 × 107 cells/ml in phosphate-buffered saline (PBS) for 20 min
on ice. Reactions were quenched by washing cells twice with PBS
containing 5 mM glycine. All cells were lysed at a density
of 5 × 107/ml in 0.5% Nonidet P-40
(Pierce)/Tris-buffered saline buffer (lysis buffer) and incubated for
20 min on ice. Post-nuclear supernatants were incubated with
I3/2-coupled Sepharose 4B for 1-2 h or with 10 µl/ml rabbit
antiserum, followed by capture of the immune complexes with protein
A-Sepharose 4B. Biotinylated proteins were isolated by incubation with
streptavidin-agarose for 1-2 h at 4 °C. Immunoprecipitates and
streptavidin pull-downs were washed three times with radioimmune precipitation assay buffer. After washing, the immunoprecipitates were
boiled in reducing sample buffer. Immunoprecipitates were treated with
Endo H (Calbiochem) in PBS containing 1% Nonidet P-40, 0.1% SDS, and
1% 2-mercaptoethanol for 16 h at 33 °C.
Pulse-Chase Analysis, Isolation of Cell-surface Proteins, and
Brefeldin A Treatment--
Cells were washed twice with PBS prior to
depletion of intracellular methionine by incubation for 30 min at
37 °C with methionine-free RPMI 1640 medium (Invitrogen). Cells were
then pulsed for 10 min at 15 °C or for 5 min at 37 °C (pulse
conditions are indicated for each figure) with 0.5 mCi/ml
Tran35S-label (ICN Biomedicals) at 5 × 107/ml. Cells were washed twice with ice-cold unlabeled
complete medium (containing methionine) prior to initiation of the
chase. Cells were chased at 37 °C (or as indicated) in complete
medium, followed by washing with PBS prior to lysis. Where indicated, the chase medium was supplemented with 10 mM methionine.
All cells were kept on ice after the chase prior to isolation of the
cell-surface protein as described below to prevent antibody or biotin
internalization. For specific isolation of cell-surface proteins,
either an antibody or biotinylation method was employed. For isolation
of cell-surface protein by the antibody method, cells were incubated
for 20 min with 20 µg/ml I3/2 or 10 µl/ml rabbit antiserum at
4 °C, followed by washing three times with PBS. Cells (5 × 106) were then lysed with 500 µl of 2.5 × 107/ml unlabeled lysate. Immune complexes were recovered
with secondary antibody-coated protein A-Sepharose 4B. For isolation of
cell-surface CD45 by biotinylation, cells were surface-biotinylated as
described above and lysed at 2.5 × 107/ml in lysis
buffer, followed by total CD45 immunoprecipitation. Captured
CD45 was released by boiling for 2 × 5 min in 50 µl of 2%
SDS-containing Tris-buffered saline. Eluent was diluted to 1 ml with
lysis buffer. Biotinylated CD45 was isolated with immobilized streptavidin as described above. Cell-surface proteins were selectively isolated by the antibody method unless otherwise stated. All
immunoprecipitates and pull-downs were washed three times with
radioimmune precipitation assay buffer prior to boiling with reducing
sample buffer. In the cases where brefeldin A (BFA) was used to block
protein trafficking, cells were preincubated with 2 µg/ml BFA for 30 min at 37 °C. BFA was also present during the pulse-chase at 2 µg/ml.
Polyacrylamide Gel Electrophoresis, Autoradiography, and
Immunoblotting--
Proteins were resolved on polyacrylamide gels and
transferred to Immobilon (polyvinylidene difluoride; Millipore Corp.,
Bedford, MA) as described previously (23). For separation under
nonreducing conditions, 2-mercaptoethanol was omitted from the sample
buffer. Autoradiography was performed with the BioMax TranScreen
intensifying system (Eastman Kodak Co.). Western blot analysis was
conducted with the indicated antiserum followed by horseradish
peroxidase-conjugated protein A (Pierce) and visualized by ECL
(PerkinElmer Life Sciences). Densitometry was performed using NIH Image
Version 1.62 software.
FACS Analysis--
Cells (1 × 106) were
incubated with 10 µl/ml antiserum H2 for 20 min on ice, followed by
two washes with PBS containing 0.1% serum. For detection of bound
antibody, cells were further incubated with fluorescein
isothiocyanate-conjugated donkey anti-rabbit antibody for an additional
20 min on ice. Cells were then fixed in 1% paraformaldehyde before analysis.
 |
RESULTS |
CD45 Acquires Endo H Resistance Quickly after
Synthesis--
Because CD45 is capable of reaching the cell surface
with incompletely processed carbohydrate (7, 12), we wished to follow the processing of CD45 carbohydrate through the secretory pathway using
the acquisition of Endo H resistance as a marker of protein location.
Treatment of newly synthesized CD45 with Endo H after various chase
times indicated that CD45 began to acquire Endo H resistance ~15 min
after synthesis and that 80% of newly synthesized CD45 was Endo
H-resistant after 60 min (Fig. 1). Class
I MHC showed a lag period before acquiring Endo H resistance (Fig. 1).
This lag phase in glycoprotein trafficking seen with Class I MHC may reflect the requirement for peptide loading,
2-microglobulin association, and transport to the
Golgi before Class I begins to achieve Endo H resistance. It should be
noted at this point that CD45 never achieved full Endo H resistance,
with ~50% of its carbohydrate remaining Endo H-sensitive (Fig.
1).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
CD45 achieves Endo H resistance rapidly after
synthesis. BW cells were pulsed for 10 min at 15 °C and chased
at 37 °C. Total CD45 (upper two panels) or Class I MHC
(lower two panels) was immunoprecipitated (ip.)
from the lysates and either mock-treated (M) or subjected to
Endo H digestion (H) prior to resolving by SDS-PAGE.
Autoradiography and Western blot (WB) analysis were
performed as indicated.
|
|
Two Pools of CD45 Appear on the Cell Surface, Each with Different
Kinetics--
In addition to determining the rate of acquisition of
Endo H resistance, another key parameter in the trafficking of CD45 is
the time required to reach the cell surface. By ascertaining the time
required to reach the plasma membrane, we can observe whether or not
CD45 traffics directly from the Golgi to the cell surface, or if a
route through other compartments occurs. Initial experiments performed
to address the time required for newly synthesized CD45 to reach the
plasma membrane indicated that a population of newly synthesized CD45
was able to traffic to the surface during a 5-min pulse at 37 °C
(data not shown). This time to cell-surface expression seems to be
extremely rapid compared with the kinetics reported for the majority of
other cell-surface proteins. However, Nori and Stallcup (28) used CD45
as a control in a pulse-chase experiment and reported similar results
with respect to rapid CD45 cell-surface expression. To more accurately
determine the time required for newly synthesized CD45 to reach the
cell surface, a modification to the previous pulse-chase protocol was
necessary. A pulse condition was needed that prevented or substantially
slowed bulk protein transport, but still allowed for sufficient
incorporation of metabolic label. Incubation of cells at 15 °C has
previously been demonstrated to block protein transport at the ER-Golgi
intermediate compartment (ERGIC) (29); therefore, pulsing cells with
[35S]methionine at 15 °C instead of 37 °C should
slow protein transport enough to reveal a true zero chase time for
cell-surface expression. Using this new protocol, no radiolabeled CD45
was detected on the cell surface at time 0 (Fig.
2A). By 5 min, a lower
molecular weight population of newly synthesized CD45 appeared at the
plasma membrane, whereas a higher molecular weight population reached the cell surface at ~15 min. The amount of newly synthesized, higher
molecular weight CD45 isolated from the cell surface increased through
60 min, whereas the amount of the lower molecular weight population
remained fairly constant after 15 min. As determined by densitometric
analysis, at 60 min, the lower molecular weight population of newly
synthesized cell-surface CD45 composed ~20% of the total newly
synthesized cell-surface material; and in examining the steady-state
levels of surface CD45, the lower form was ~20% of the total (Fig.
2A). We also observed that the total amount of newly
synthesized CD45 increased over the chase time, which raises the
possibility that labeled CD45 continues to be synthesized over the
chase or that, because the antibody used to isolate CD45 is
conformation-dependent, this increase may reflect an
increase in the amount of folded CD45. Because the inclusion of 10 mM methionine during the chase did not prevent the increase
in labeled CD45 isolated over the chase (Fig. 2A,
expt. 2), we suspect that the increase in labeled CD45
recovered is due to an increased ability of the antibody to recognize
CD45 over the chase time.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2.
Two forms of newly synthesized CD45 can be
isolated from the cell surface by the antibody method, each with
distinct trafficking kinetics. A, BW cells were pulsed
for 10 min with [35S]methionine at 15 °C, followed by
chasing in unlabeled complete medium at 37 °C. In Experiment 1 (expt. 1), no excess methionine was included in the chase
medium, whereas in Experiment 2 (expt. 2), the chase medium
was supplemented with 10 mM methionine. Cell-surface CD45
was isolated by the antibody method, and the remaining CD45 was
captured with I3/2-coated beads. Proteins were separated by SDS-PAGE,
followed by autoradiography and Western blot (WB) analysis.
B, 2 50.5 cells were pulsed for 5 min at 37 °C,
followed by chasing at 37 °C in unlabeled complete medium. The chase
medium was supplemented with 10 mM methionine in Experiment
2 only. Surface CD45 was isolated by the antibody method, and the
remaining CD45 was recovered with I3/2-coated beads. Proteins were
resolved by SDS-PAGE, followed by autoradiography and Western blot
analysis. C, BW cells were pulsed at 15 °C for 10 min,
followed by chasing at 37 °C in complete medium. Surface Class I MHC
was isolated by the antibody method and separated by SDS-PAGE.
Autoradiography and Western blot analysis were performed.
ip., immunoprecipitate.
|
|
It still remains possible that, during the cell-surface isolation of
newly synthesized CD45, we were recovering internal pools of labeled
CD45 nonspecifically. This may be particularly problematic at
the early time points. For a number of reasons, we feel that this
possibility is unlikely. Perhaps the most compelling argument against
this possibility is that, using the same isolation protocol with a
fibroblast cell line transfected with CD45, we were unable to recover
newly synthesized cell-surface CD45 until 30 min, even though a
significant amount of newly synthesized CD45 could be recovered over
the chase time (Fig. 2B). In fact, with this cell line,
cells were pulsed for 5 min at 37 °C before initiating the chase;
and even with this pulse procedure, a rapidly expressed population of
CD45 was not detected (Fig. 2B). Additionally, there appears
to be only one glycoform of CD45 isolated from these cells, in contrast
to the two forms isolated from the BW cell line. Furthermore, using
Class I MHC as a control for the protocol, the surface expression of
newly synthesized Class I MHC followed trafficking kinetics similar to
those previously reported (30, 31), with no newly synthesized Class I
MHC being isolated from the cell surface until 30 min of chase time
(Fig. 2C). Finally, control mixing experiments in which
unlabeled surface protein was isolated in the presence of labeled
lysates showed that barely detectable levels of labeled material
(significantly lower than the amount we detected at the early time
points in Fig. 2A) were isolated with the unlabeled cell-surface complexes (data not shown).
Another published method to isolate cell-surface proteins involves
surface biotinylation and isolation of the protein of interest, followed by streptavidin affinity enrichment (15, 32). Using the
surface biotinylation approach to isolate cell-surface CD45, we
obtained results similar to those attained with the surface antibody
method described above (Fig.
3A). Newly synthesized
surface-biotinylated CD45 began to appear on the cell surface at 5 min
and increased through to 60 min of chase time, with the existence of
two different forms (Fig. 3A). Between experiments and
surface CD45 isolation protocols, the only variability in results
occurred in the amount of the higher molecular weight form of CD45
isolated at 15 min. To control for possible nonspecific isolation of
cell-surface CD45 by the biotinylation method, two controls were
performed. First, a cytosolic protein-tyrosine kinase (Pyk-2) was
immunoprecipitated from a surface-biotinylated lysate or a lysate
biotinylated after detergent solubilization. Pyk-2 was found to be
biotinylated only in the case where biotin was added post-lysis, not
during the surface biotinylation procedure (Fig. 3B).
Second, non-biotinylated CD45 eluted from a CD45 immunoprecipitate was
not captured by streptavidin-coated beads (Fig. 3C).
Therefore, it appears that there is a rapidly expressed population of
CD45 in BW cells and that the mechanism used to express this form of
CD45 does not exist in all cell types.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Isolation of cell-surface CD45 by surface
biotinylation reveals two different forms of newly synthesized
CD45. A, BW cells were pulsed for 10 min at 15 °C
and chased at 37 °C in complete medium. In Experiment 1 (expt.
1), no excess methionine was present during the chase; but in
Experiment 2 (expt. 2), the chase medium was supplemented
with 10 mM methionine. Cells were biotinylated on ice for
20 min prior to lysis. Total CD45 was immunoprecipitated and eluted
from I3/2-coated beads by boiling in 2% SDS-containing PBS for 10 min,
and a streptavidin pull-down assay was performed on the eluted
material. Material bound to streptavidin-coated beads was resolved by
SDS-PAGE and subjected to autoradiography and Western blot
(WB) analysis. B, Pyk-2 immunoprecipitates
(ip.) from a surface-biotinylated cell lysate (lane
1) or a lysate biotinylated after lysis (lane 2) were
resolved by SDS-PAGE. Western blotting with streptavidin
(SA; upper panel) and Pyk-2 (lower
panel) was performed. C, I3/2 immunoprecipitation from
non-biotinylated BW lysates was performed. The CD45
immunoprecipitate (lane 1) or a streptavidin pull-down from
the elution of the CD45 immunoprecipitate (lane 2) was
resolved by SDS-PAGE. The presence of CD45 was determined by Western
blot analysis.
|
|
The Rapidly Expressed, Lower Molecular Weight Cell-surface CD45 Is
Endo H-sensitive, whereas the Higher Molecular Weight Form Is Endo
H-resistant--
Because bulk CD45 acquired Endo H resistance rapidly
after synthesis and there were two different forms of CD45 expressed on
the cell surface with different kinetics, we wished to determine whether both forms were in fact Endo H-resistant or if one was possibly
Endo H-sensitive. To determine the carbohydrate status of the two
different forms of newly synthesized cell-surface CD45, surface CD45
was isolated after pulse-chase and subjected to Endo H treatment. The
rapidly expressed population of CD45 was entirely Endo H-sensitive,
whereas the higher molecular weight form achieved its full Endo H
resistance (Fig. 4). These data suggest
that the higher molecular weight form is a mature glycoform of CD45
with fully processed carbohydrate, whereas the lower molecular weight form is an immature glycoform with unprocessed carbohydrate. Note again
that the fully processed glycoform of CD45 still contains a significant
fraction of Endo H-sensitive carbohydrate, but mature cell-surface CD45
always appears to contain this level of Endo H-sensitive carbohydrate
in these cells (7).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
Rapidly expressed, newly synthesized
cell-surface CD45 contains exclusively Endo H-sensitive carbohydrate,
whereas the majority of newly synthesized cell-surface CD45 contains
Endo H-resistant carbohydrate. BW cells were pulsed for 10 min at
15 °C and chased at 37 °C, followed by isolation of cell-surface
CD45 by the antibody method. The immune complexes were split into two
fractions and either mock-treated (M) or treated with Endo H
(H). The resultant proteins were separated by SDS-PAGE, and
autoradiography was performed (upper panel). Western blot
(WB) analysis of the total protein is shown as a control
(lower panel).
|
|
The Rapidly Expressed Pool of CD45 Reaches the Cell Surface by a
BFA-insensitive Mechanism--
The finding that CD45 was capable of
reaching the cell surface without complete processing of its
carbohydrate raises the question of how this material traffics from the
ER to the cell surface. The prevailing model of glycoprotein transport
states that once a glycoprotein leaves the ER, it is transported
through the ERGIC to the Golgi, where the carbohydrate is processed to a complex form, and finally to the cell surface. Our finding that the
rapidly expressed pool of CD45 reached the cell surface with exclusively unprocessed N-linked carbohydrate
suggests that this pool may by-pass the Golgi entirely en route to the
cell surface. One of the most well characterized and commonly used
methods to inhibit protein transport through the Golgi is treatment of
cells with the fungal metabolite BFA. BFA interferes with the
recruitment of the ADP-ribosylation factor-1 GTPase to
COPI-coated membranes, effectively blocking protein transport through
the prevention of ER export and subsequent Golgi redistribution (33,
34). Treatment of cells with BFA effectively inhibited Class I MHC cell-surface expression and the trafficking of the higher molecular weight mature glycoform of CD45, indicating that the BFA-induced blockade was successful; however, it did not inhibit the transport of
the rapidly expressed, lower molecular weight glycoform of CD45 to the
cell surface (Fig. 5). Examination of the
carbohydrate on newly synthesized CD45 after BFA treatment revealed
that it contained entirely Endo H-sensitive carbohydrate, as expected (Fig. 5). These data suggest that the rapidly expressed population of
CD45 reaches the cell surface independent of the Golgi complex and does
not rely on a BFA-sensitive transport mechanism. As we did not observe
increasing amounts of CD45 reaching the cell surface after BFA
treatment, and the amount of cell-surface CD45 appeared fixed at
~20% in the presence of BFA, the data suggest that there is an early
commitment of a significant portion of CD45 to the conventional
transport pathway. Apparently, once it enters the conventional pathway,
CD45 cannot be expressed on the cell surface in the presence of BFA by
the rapid alternative pathway.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
Surface expression of the lower molecular
weight form of CD45 is resistant to BFA treatment. BW cells were
pretreated with 2 µg/ml BFA for 30 min at 37 °C, followed by
pulsing at 15 °C for 10 min and chasing at 37 °C. BFA was present
at the same level during the pulse-chase times. Cell-surface CD45
(first and second panels) or Class I MHC
(third and fourth panels) was isolated by the
antibody method. The immune complexes were resolved by SDS-PAGE and
subjected to autoradiography, followed by Western blot (WB)
analysis with the indicated antisera. The remaining CD45 was
immunoprecipitated and either mock-treated (M) or treated
with Endo H (H) (fifth panel). Proteins
were separated by SDS-PAGE, followed by autoradiography and Western
blotting.
|
|
Both 15 and 20 °C Blockades Result in Delayed Trafficking
Kinetics of the Rapidly Expressed Pool of Cell-surface CD45--
To
further dissect the pathway used by the rapidly expressed pool of CD45,
we took advantage of blocks at the ERGIC and TGN imposed by chasing
proteins at 15 and 20 °C, respectively (29, 35, 36). Performing the
chase at 15 °C resulted in delayed and reduced expression of the
lower molecular weight form of CD45, whereas this treatment completely
prevented the surface expression of the higher molecular weight form of
CD45 and Class I MHC, indicating that the blockade was successful (Fig.
6A). Chasing cells at 20 °C
after pulsing at 15 °C and isolation of cell-surface CD45 resulted in the appearance of the lower molecular weight form of CD45 beginning at 15 min and increasing through the entire chase time (Fig.
6B). By chasing at 20 °C, both the higher molecular
weight form of CD45 and Class I MHC were prevented from reaching the
plasma membrane, indicating that the kinetic block was functional (Fig.
6B). Examination of the remaining CD45 after the chase at 15 or 20 °C revealed that it still contained predominantly Endo
H-sensitive carbohydrate (Fig. 6, A and B). The
observation of reduced kinetics of acquisition of Endo H resistance is
in accordance with previously published data (35). Therefore, it
appears that a block of glycoprotein traffic through the
cis-Golgi or at the TGN does not prevent the expression of
the lower molecular weight form of CD45, but it does appear to delay
its trafficking kinetics.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 6.
Expression of the lower molecular weight form
of CD45 is delayed by a 15 or 20 °C chase. A, cells
were pulsed at 15 °C for 10 min, followed by chasing at either 37 or
15 °C. Cell-surface CD45 (first and second
panels) or Class I MHC (third and fourth
panels) was isolated by the antibody method and separated by
SDS-PAGE. Autoradiography was performed, followed by Western blot
(WB) analysis. B, BW cells were pulsed for 10 min
at 15 °C and chased at 20 °C. Cell-surface CD45 (first
and second panels) or Class I MHC (third and
fourth panels) was isolated by the antibody method and
resolved by SDS-PAGE. Autoradiography and Western blot analysis were
performed. For both A and B, the remaining CD45
was immunoprecipitated and either mock-treated (M)
or subjected to Endo H digestion (H) (fifth
panels). The resultant proteins were separated by SDS-PAGE, and
autoradiography was performed.
|
|
GII, a Putative Resident ER Protein, Traffics Rapidly to the Cell
Surface and Possesses Immature Carbohydrate--
Because CD45 and GII
associate stably in the BW cells used for this study and a number of
other putative resident ER proteins have been found on the cell surface
of numerous cell types (37-40), we wished to determine whether GII is
expressed on the cell surface. To first determine whether GII is
present on the cell surface, FACS analysis was performed with an
antiserum specific for GII . The data in Fig.
7A clearly show that GII
was expressed on the cell surface. Given the finding of GII on the
surface by FACS analysis, we wanted to determine the kinetics of
expression of GII at the plasma membrane. Isolation of surface GII by
the antibody method using anti-GII antiserum after pulse-chase
revealed rapid surface expression of GII (Fig. 7B). Newly
synthesized GII was detected at the plasma membrane 5 min after
synthesis, with a further increase at 15 min, after which time the
levels remained relatively constant. There did appear to be more newly
synthesized GII on the cell surface at 30 and 60 min, but there also
appeared to be more GII recovered at those time points (Fig.
7B). Because GII is glycosylated, we could assess the
status of the carbohydrate expressed by surface GII to determine
whether surface GII expresses N-linked carbohydrate
processed in the Golgi. To this end, a lysate from surface-biotinylated
cells was incubated with streptavidin-coated beads to specifically
enrich the surface proteins. Endo H and F analyses were performed, and
GII was again found on the surface by this protocol and possessed
entirely Endo H-sensitive carbohydrate (Fig. 7C). Another
glycosylated ER protein found on the surface is grp94, and the
carbohydrate on grp94 isolated from the cell surface was also
exclusively Endo H-sensitive (Fig. 7C). Therefore, it
appears that the resident ER enzyme GII and grp94 are expressed on the
cell surface and express carbohydrate that has not been processed in
the Golgi.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
GII traffics rapidly to the cell
surface. A, 1 × 106 cells were
incubated with 2 µl of anti-GII antiserum on ice for 20 min,
followed by fluorescein isothiocyanate-conjugated protein A. The
shaded area represents control staining with an antiserum
specific for the intracellular domains of CD45. B, cells
were pulsed for 10 min at 15 °C and chased at 37 °C in complete
medium. Surface GII was isolated by the antibody method with
anti-GII antiserum. Immune complexes were captured with protein
A-Sepharose 4B and resolved by SDS-PAGE. Autoradiography and Western
blot (WB) analysis were performed. C, lysate from
surface-biotinylated cells was incubated with streptavidin-agarose.
Recovered proteins were either mock-treated (M) or
subjected to Endo H (H) or Endo F (F) treatment
under reducing and denaturing conditions. Proteins were resolved by
SDS-PAGE, and Western blotting was performed with antisera specific for
the indicated proteins.
|
|
 |
DISCUSSION |
We have previously demonstrated that CD45 reaches the plasma
membrane with incompletely processed carbohydrate and that
mannose-binding lectin can recognize this cell-surface CD45 (7).
Because of recent reports implicating carbohydrate in the regulation of
cellular processes and the importance of CD45 in T cell function, we
have further investigated the transport pathway utilized by CD45 in hopes of determining the mechanism by which CD45 can reach the cell
surface with immature carbohydrate.
Unexpectedly, in examining the trafficking of CD45, we observed a
striking pattern of CD45 cell-surface expression. There appears to be
two different glycoforms of CD45 that reach the cell surface, each with
different kinetics. The lower molecular weight glycoform arrived within
5 min and achieved maximum expression at 15 min, whereas the higher
molecular weight form appeared after 15 min and increased through 60 min. The rapidity with which both forms reached the cell surface
compared with other cell-surface glycoproteins is quite surprising.
This rapid trafficking of CD45 was confirmed by examining the rate of
acquisition of Endo H resistance. As illustrated in Fig. 1, there was a
short lag period in the time required for CD45 to begin to acquire Endo
H resistance. This suggests that CD45 does not remain in the ER long
after synthesis; rather, it traffics quickly to the Golgi, where its
carbohydrate can be processed.
Interestingly, the rapidly expressed, lower molecular weight pool of
CD45 contained exclusively Endo H-sensitive carbohydrate, whereas the
higher molecular weight CD45 possessed mature carbohydrate (Fig. 4).
This finding suggests that the rapidly expressed pool by-passes the
Golgi complex, where the enzymes required to convert N-linked carbohydrate from Endo H-sensitive to Endo
H-resistant reside. It has been suggested that the minimal time
required for transit through the Golgi is 10 min (30), and the finding
that the rapidly expressed pool appeared after 5 min supports the
hypothesis that this pool of CD45 may by-pass the Golgi. In addition,
treatment of cells with BFA, which disrupts the Golgi, still permitted
the expression of the lower molecular weight CD45 on the cell surface, whereas the higher molecular weight CD45 and Class I MHC were completely prevented from trafficking to the plasma membrane. Finally,
a block at the TGN resulted in abrogation of the higher molecular
weight CD45 and Class I MHC from the cell surface, but the lower
molecular weight CD45 still appeared. Collectively, these data support
the by-pass of the Golgi complex by the rapidly expressed, lower
molecular weight cell-surface CD45.
Given the above data, we suggest there are two possible means by which
the rapidly expressed population of CD45 could reach the plasma
membrane. The first involves a direct fusion event between peripheral
components of the ER and the plasma membrane. The second involves a
vesicle-mediated transport mechanism. Recently, Gagnon et
al. (41) demonstrated a direct ER-to-plasma membrane fusion event
during phagosome formation. They found putative resident ER proteins
including calnexin in the early phagosome. From this work, they
concluded that the plasma membrane is not the only contributor to
phagosome formation, but that through direct fusion, the ER provides a
source of membrane (41). It has also been found by examination of the
internal architecture of the cell that elements of the ER can be found
closely juxtaposed to the plasma membrane (42). If newly synthesized
CD45 in the ER were found at the site of direct ER-to-plasma membrane
fusion, it would reach the cell surface rapidly without transport
through the Golgi. In addition, disruption of the Golgi would likely
not have any effect on the ability of CD45 to reach the cell surface by
this mechanism, nor would any of the kinetic transport blocks have any
effect. This direct fusion event could also explain the finding of
newly synthesized GII on the cell surface (containing Endo H-sensitive
carbohydrate) as well as the mechanism by which the numerous resident
ER proteins are found at the plasma membrane (37-40). Finally,
the direct fusion could also explain why we detected rapid cell-surface
expression of CD45 in BW cells, but not fibroblast cells. One would
expect that, because of the more compact architecture of lymphoid
cells, ER components would more frequently contact cell-surface
membranes in BW cells, whereas in the much larger, less densely packed
fibroblast cells, the frequency of the ER membrane contacting the
plasma membrane would be predicted to be much lower. Thus, a direct
fusion of the ER with the plasma membrane could account for our observations.
Alternatively, a bona fide vesicle-mediated transport
mechanism could also be reconciled with our data. There are a few
examples of transport pathways that by-pass the Golgi, including
rotaviral production and cystic fibrosis transmembrane conductance
regulator (CFTR) transport. Examination of CFTR trafficking
demonstrated that there is a 2-fold decrease of CFTR in the Golgi
compared with the ER, with limited amounts in both the
cis-Golgi and TGN (43). Subsequently, it was also observed
that CFTR export requires the machinery of the early secretory pathway,
namely COPII, but that after leaving the ER in COPII vesicles, the
remaining transport utilizes a non-conventional pathway
(44). In examining rotaviral particle release, it was observed that
viral particle production is dependent on the ER; however, disruption
of the Golgi complex by treatment with monensin has no impact on viral
particle release (45). Interestingly, cholesterol transport has
recently been demonstrated to occur in a BFA-insensitive manner.
Cholesterol reached the cell surface with a half-time of ~10
min, but its expression was reduced by a 15 °C chase (46). These
characteristics are reminiscent of the transport kinetics and BFA
sensitivity shown by the rapidly expressed pool of CD45.
In examining the effect of BFA on the disruption of Golgi structure, it
has been observed that different Golgi constituents re-localize to
different areas of the cell post-BFA treatment (47). BFA prevents
transport by inhibiting a guanine nucleotide exchange factor for the
ADP-ribosylation factor-1 GTPase, which is thought to be required for
the recruitment of COPI to the vesicle membrane. Interestingly,
examination of the ER has revealed that BFA has little to no impact on
the structure of ER exit sites (48). ER exits sites are believed to be
the place where vesicles bearing cargo leave the ER for trafficking to
the intermediate compartment. Because BFA has little impact on the
structure of ER exit sites, it is conceivable that vesicles with no
requirement for BFA-sensitive COPI trafficking and containing
cargo destined for the cell surface independent of the Golgi would be
able to effectively reach the cell surface in the presence of BFA. In support of a COPI-independent transport route from the ER to the ERGIC,
work by Scales et al. (49) demonstrated the sequential action of COPII and COPI for ER-to-ERGIC trafficking and ERGIC-to-Golgi trafficking, respectively. In the event that COPI is required for
ER-to-ERGIC transport, a BFA-resistant guanine nucleotide exchange
factor for ADP-ribosylation factor-1 was recently cloned (50). In
support of either a COPI-independent or BFA-resistant COPI-dependent mode of transport, a member of the connexin
family of gap junction proteins was also shown to traffic to the cell surface in a BFA-insensitive manner (51). In addition, with respect to
CFTR trafficking, a dominant-negative ADP-ribosylation factor-1
construct had no effect on the transport of CFTR (44) Therefore, a
BFA-insensitive guanine nucleotide exchange factor or a
COPI-independent mechanism may be responsible for the trafficking of
the rapidly expressed pool of CD45 to the cell surface.
The expression of cell-surface CD45 containing exclusively
unprocessed carbohydrate is somewhat unexpected; however, this pool of
CD45 may have important biological implications. The lower molecular
weight, fully Endo H-sensitive form of CD45 was detected on the cell
surface at steady-state levels (Fig. 2B), suggesting this is
a constitutive pathway resulting in a stable pool of protein. Consistent with the stable expression of the lower molecular weight form on the cell surface, we have found that both glycoforms of CD45
expressed on the cell surface of BW cells are recognized by the
mannose-binding lectin (7). Lectin recognition of CD45 could have many
implications in T cell biology, including the modulation of adhesion,
cell migration, mobility of CD45 within the plasma membrane, and
signaling thresholds.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Kevin Kane for the generous gift
of the anti-Class I MHC antiserum and critical review of the
manuscript. We also thank Dr. Tom Hobman (University of Alberta) for
providing thoughtful suggestions and insights.
 |
FOOTNOTES |
*
This work was supported in part by an operating grant from
the Canadian Institutes of Health Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by a studentship from the Alberta Heritage Foundation
for Medical Research.
§
Alberta Heritage Foundation for Medical Research Senior Scientist.
To whom correspondence should be addressed: Dept. of Medical Microbiology and Immunology, 6-70 HMRC, University of Alberta, Edmonton, Alberta T6G 2S2, Canada. Tel.: 780-492-7710; Fax:
780-492-9828; E-mail: hanne.ostergaard@ualberta.ca.
Published, JBC Papers in Press, October 16, 2002, DOI 10.1074/jbc.M209075200
 |
ABBREVIATIONS |
The abbreviations used are:
ER, endoplasmic
reticulum;
GII, glucosidase II;
TGN, trans-Golgi network;
MHC, major histocompatibility complex;
Endo H, endoglycosidase H;
PBS, phosphate-buffered saline;
BFA, brefeldin A;
FACS, fluorescence-activated cell sorter;
ERGIC, endoplasmic reticulum-Golgi
intermediate compartment;
COP, coat protein complex;
CFTR, cystic fibrosis transmembrane conductance regulator.
 |
REFERENCES |
| 1.
|
Byth, K. F.,
Conroy, L. A.,
Howlett, S.,
Smith, A. J.,
May, J.,
Alexander, D. R.,
and Holmes, N.
(1996)
J. Exp. Med.
183,
1707-1718[Abstract/Free Full Text]
|
| 2.
|
Trowbridge, I. S.,
and Thomas, M. L.
(1994)
Annu. Rev. Immunol.
12,
85-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Thomas, M. L.,
and Brown, E. J.
(1999)
Immunol. Today
20,
406-411[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Ashwell, J. D.,
and D'Oro, U.
(1999)
Immunol. Today
20,
412-416[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Thomas, M. L.
(1989)
Annu. Rev. Immunol.
7,
339-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Pulido, R.,
and Sanchez-Madrid, F.
(1992)
Eur. J. Immunol.
22,
463-468[Medline]
[Order article via Infotrieve]
|
| 7.
|
Baldwin, T. A.,
and Ostergaard, H. L.
(2001)
J. Immunol.
167,
3829-3835[Abstract/Free Full Text]
|
| 8.
|
Stamenkovic, I.,
Sgroi, D.,
Aruffo, A., Sy, M. S.,
and Anderson, T.
(1991)
Cell
66,
1133-1144[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Sgroi, D.,
Koretzky, G. A.,
and Stamenkovic, I.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4026-4030[Abstract/Free Full Text]
|
| 10.
|
Pace, K. E.,
Lee, C.,
Stewart, P. L.,
and Baum, L. G.
(1999)
J. Immunol.
163,
3801-3811[Abstract/Free Full Text]
|
| 11.
|
Perillo, N. L.,
Pace, K. E.,
Seilhamer, J. J.,
and Baum, L. G.
(1995)
Nature
378,
736-739[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Uemura, K.,
Yokota, Y.,
Kozutsumi, Y.,
and Kawasaki, T.
(1996)
J. Biol. Chem.
271,
4581-4584[Abstract/Free Full Text]
|
| 13.
|
Lippincott-Schwartz, J.,
Roberts, T. H.,
and Hirschberg, K.
(2000)
Annu. Rev. Cell Dev. Biol.
16,
557-589[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Roche, P. A.
(1999)
Immunity
11,
391-398[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Briken, V.,
Jackman, R. M.,
Dasgupta, S.,
Hoening, S.,
and Porcelli, S. A.
(2002)
EMBO J.
21,
825-834[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Pieters, J.
(1997)
Biol. Chem. Hoppe-Seyler
378,
751-758
|
| 17.
|
Pamer, E.,
and Cresswell, P.
(1998)
Annu. Rev. Immunol.
16,
323-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Geijtenbeek, T. B.,
Torensma, R.,
van Vliet, S. J.,
van Duijnhoven, G. C.,
Adema, G. J.,
van Kooyk, Y.,
and Figdor, C. G.
(2000)
Cell
100,
575-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Geijtenbeek, T. B. H.,
Krooshoop, J. E. B.,
Bleijs, D. A.,
van Vliet, S. J.,
van Duijnhoven, G. C. F.,
Brabovsky, V.,
Alon, R.,
Figdor, C. G.,
and van Kooyk, Y.
(2000)
Nat. Immunol.
1,
353-357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Daniels, M. A.,
Devine, L.,
Miller, J. D.,
Moser, J. M.,
Lukacher, A. E.,
Altman, J. D.,
Kavathas, P.,
Hogquist, K. A.,
and Jameson, S. C.
(2001)
Immunity
15,
1051-1061[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Moody, A. M.,
Chui, D.,
Reche, P. A.,
Priatel, J. J.,
Marth, J. D.,
and Reinherz, E. L.
(2001)
Cell
107,
501-512[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Demetriou, M.,
Granovsky, M.,
Quaggin, S.,
and Dennis, J. W.
(2001)
Nature
409,
733-739[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Arendt, C. W.,
and Ostergaard, H. L.
(1995)
J. Biol. Chem.
270,
2313-2319[Abstract/Free Full Text]
|
| 24.
|
Johnson, P.,
Greenbaum, L.,
Bottomly, K.,
and Trowbridge, I. S.
(1989)
J. Exp. Med.
169,
1179-1184[Abstract/Free Full Text]
|
| 25.
|
Maksymowych, W. P.,
Ikawa, T.,
Yamaguchi, A.,
Ikeda, M.,
McDonald, D.,
Laouar, L.,
Lahesmaa, R.,
Tamura, N.,
Khuong, A., Yu, D. T.,
and Kane, K. P.
(1998)
Infect. Immun.
66,
4624-4632[Abstract/Free Full Text]
|
| 26.
|
Baldwin, T. A.,
Gogela-Spehar, M.,
and Ostergaard, H. L.
(2000)
J. Biol. Chem.
275,
32071-32076[Abstract/Free Full Text]
|
| 27.
|
Berg, N. N.,
and Ostergaard, H. L.
(1997)
J. Immunol.
159,
1753-1757[Abstract]
|
| 28.
|
Nori, M.,
and Stallcup, M. R.
(1988)
Mol. Cell. Biol.
8,
833-842[Abstract/Free Full Text]
|
| 29.
|
Saraste, J.,
and Kuismanen, E.
(1984)
Cell
38,
535-549[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Williams, D. B.,
Swiedler, S. J.,
and Hart, G. W.
(1985)
J. Cell Biol.
101,
725-734[Abstract/Free Full Text]
|
| 31.
|
Williams, D. B.,
Borriello, F.,
Zeff, R. A.,
and Nathenson, S. G.
(1988)
J. Biol. Chem.
263,
4549-4560[Abstract/Free Full Text]
|
| 32.
|
Hobman, T. C.,
Woodward, L.,
and Farquhar, M. G.
(1993)
J. Cell Biol.
121,
269-281[Abstract/Free Full Text]
|
| 33.
|
Donaldson, J. G.,
Finazzi, D.,
and Klausner, R. D.
(1992)
Nature
360,
350-352[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Helms, J. B.,
and Rothman, J. E.
(1992)
Nature
360,
352-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Griffiths, G.,
Pfeiffer, S.,
Simons, K.,
and Matlin, K.
(1985)
J. Cell Biol.
101,
949-964[Abstract/Free Full Text]
|
| 36.
|
Griffiths, G.,
and Simons, K.
(1986)
Science
234,
438-443[Abstract/Free Full Text]
|
| 37.
|
Arosa, F. A.,
de Jesus, O.,
Porto, G.,
Carmo, A. M.,
and de Sousa, M.
(1999)
J. Biol. Chem.
274,
16917-16922[Abstract/Free Full Text]
|
| 38.
|
Mezghrani, A.,
Courageot, J.,
Mani, J. C.,
Pugniere, M.,
Bastiani, P.,
and Miquelis, R.
(2000)
J. Biol. Chem.
275,
1920-1929[Abstract/Free Full Text]
|
| 39.
|
Okazaki, Y.,
Ohno, H.,
Takase, K.,
Ochiai, T.,
and Saito, T.
(2000)
J. Biol. Chem.
275,
35751-35758[Abstract/Free Full Text]
|
| 40.
|
Wiest, D. L.,
Bhandoola, A.,
Punt, J.,
Kreibich, G.,
McKean, D.,
and Singer, A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1884-1889[Abstract/Free Full Text]
|
| 41.
|
Gagnon, E.,
Duclos, S.,
Rondeau, C.,
Chevet, E.,
Cameron, P. H.,
Steele-Mortimer, O.,
Paiement, J.,
Bergeron, J. J. M.,
and Desjardins, M.
(2002)
Cell
110,
119-131[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Ladinsky, M. S.,
Mastronarde, D. N.,
McIntosh, J. R.,
Howell, K. E.,
and Staehelin, L. A.
(1999)
J. Cell Biol.
144,
1135-1149[Abstract/Free Full Text]
|
| 43.
|
Bannykh, S. I.,
Bannykh, G. I.,
Fish, K. N.,
Moyer, B. D.,
Riordan, J. R.,
and Balch, W. E.
(2000)
Traffic
1,
852-870[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Yoo, J.-S.,
Moyer, B. D.,
Bannykh, S. I.,
Yoo, H.-M.,
Riordan, J. R.,
and Balch, W. E.
(2002)
J. Biol. Chem.
277,
11401-11409[Abstract/Free Full Text]
|
| 45.
|
Jourdan, N.,
Maurice, M.,
Delautier, D.,
Quero, A. M.,
Servin, A. L.,
and Trugnan, G.
(1997)
J. Virol.
71,
8268-8278[Abstract]
|
| 46.
|
Heino, S.,
Lusa, S.,
Somerharju, P.,
Ehnholm, C.,
Olkkonen, V. M.,
and Ikonen, E.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8375-8380[Abstract/Free Full Text]
|
| 47.
|
Klumperman, J.
(2000)
Nat. Cell. Biol.
2,
E217-E219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Ward, T. H.,
Polishchuk, R. S.,
Caplan, S.,
Hirschberg, K.,
and Lippincott-Schwartz, J.
(2001)
J. Cell Biol.
155,
557-570[Abstract/Free Full Text]
|
| 49.
|
Scales, S. J.,
Pepperkok, R.,
and Kreis, T. E.
(1997)
Cell
90,
1137-1148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Claude, A.,
Zhao, B. P.,
Kuziemsky, C. E.,
Dahan, S.,
Berger, S. J.,
Yan, J. P.,
Armold, A. D.,
Sullivan, E. M.,
and Melancon, P.
(1999)
J. Cell Biol.
146,
71-84[Abstract/Free Full Text]
|
| 51.
|
Martin, P. E.,
Blundell, G.,
Ahmad, S.,
Errington, R. J.,
and Evans, W. H.
(2001)
J. Cell Sci.
114,
3845-3855[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Hasegawa, L. F. Sogo, M. Tan, and C. Sutterlin
Host Complement Regulatory Protein CD59 Is Transported to the Chlamydial Inclusion by a Golgi Apparatus-Independent Pathway
Infect. Immun.,
April 1, 2009;
77(4):
1285 - 1292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bonnon, C. Bel, L. Goutebroze, B. Maigret, J.-A. Girault, and C. Faivre-Sarrailh
PGY Repeats and N-Glycans Govern the Trafficking of Paranodin and Its Selective Association with Contactin and Neurofascin-155
Mol. Biol. Cell,
January 1, 2007;
18(1):
229 - 241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Vaisanen, M.-R. Vaisanen, and T. Pihlajaniemi
Modulation of the Cellular Cholesterol Level Affects Shedding of the Type XIII Collagen Ectodomain
J. Biol. Chem.,
November 3, 2006;
281(44):
33352 - 33362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wang and R. J. Deschenes
Plasma Membrane Localization of Ras Requires Class C Vps Proteins and Functional Mitochondria in Saccharomyces cerevisiae
Mol. Cell. Biol.,
April 15, 2006;
26(8):
3243 - 3255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Cauvi, X. Tian, K. von Loehneysen, and M. W. Robertson
Transport of the IgE Receptor {alpha}-Chain Is Controlled by a Multicomponent Intracellular Retention Signal
J. Biol. Chem.,
April 14, 2006;
281(15):
10448 - 10460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Hughey, J. B. Bruns, C. L. Kinlough, and T. R. Kleyman
Distinct Pools of Epithelial Sodium Channels Are Expressed at the Plasma Membrane
J. Biol. Chem.,
November 19, 2004;
279(47):
48491 - 48494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Monick, T. O. Yarovinsky, L. S. Powers, N. S. Butler, A. B. Carter, G. Gudmundsson, and G. W. Hunninghake
Respiratory Syncytial Virus Up-regulates TLR4 and Sensitizes Airway Epithelial Cells to Endotoxin
J. Biol. Chem.,
December 26, 2003;
278(52):
53035 - 53044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bonnon, L. Goutebroze, N. Denisenko-Nehrbass, J.-A. Girault, and C. Faivre-Sarrailh
The Paranodal Complex of F3/Contactin and Caspr/Paranodin Traffics to the Cell Surface via a Non-conventional Pathway
J. Biol. Chem.,
November 28, 2003;
278(48):
48339 - 48347.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|